NXP00126 May 2019 10:47
Results will be just the start.
China license,rollout & royalties, European Licensing, USA Licensing, further Cannabinoid news, Fibrosis update, then the potential of numerous avenues we don’t know about yet, DG alluded to NXP001 addressing other non targeted treatments.
For me, ‘The Hold Factor’ is the Global potential & scalability of what NXP have/are developing.
One could easily sell at MCap £90M (circa SP 20p) only to watch 002,003 etc launch, Royalties start rolling in, more ‘spin off’ drugs developed & the MCap scoot to £480M.
And during all of this the possibility of a Bid, at any time.
The next 12 months could be incredible here.